Esperion Therapeutics, Inc.
ESPR
$1.50
$0.000.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 332.31M | 295.45M | 277.79M | 229.74M | 116.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 332.31M | 295.45M | 277.79M | 229.74M | 116.33M |
| Cost of Revenue | 114.84M | 107.43M | 108.00M | 109.82M | 129.37M |
| Gross Profit | 217.48M | 188.03M | 169.78M | 119.92M | -13.04M |
| SG&A Expenses | 163.07M | 171.57M | 164.84M | 154.61M | 142.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 277.91M | 279.00M | 272.84M | 264.43M | 271.90M |
| Operating Income | 54.40M | 16.46M | 4.95M | -34.69M | -155.56M |
| Income Before Tax | -51.75M | -86.77M | -98.50M | -86.51M | -209.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.75 | -86.77 | -98.50 | -86.51 | -209.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.75M | -86.77M | -98.50M | -86.51M | -209.25M |
| EBIT | 54.40M | 16.46M | 4.95M | -34.69M | -155.56M |
| EBITDA | 54.50M | 16.53M | 5.03M | -34.57M | -155.40M |
| EPS Basic | -0.23 | -0.62 | -0.84 | -0.97 | -2.11 |
| Normalized Basic EPS | 0.04 | -0.21 | -0.35 | -0.60 | -1.32 |
| EPS Diluted | -0.25 | -0.65 | -0.86 | -0.99 | -2.12 |
| Normalized Diluted EPS | 0.01 | -0.24 | -0.37 | -0.63 | -1.32 |
| Average Basic Shares Outstanding | 748.55M | 665.39M | 582.33M | 502.78M | 411.96M |
| Average Diluted Shares Outstanding | 768.93M | 685.77M | 602.71M | 523.16M | 411.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
